ClinicalTrials.gg
RecruitingNCT06054321BMDD-2022Updated Oct 26, 2026

Psychopharmacotherapy for Depressive Patients

An interventional study of stepwise pharmacotherapy and antidepressant monotherapy group in Major Depressive Disorder, sponsored by Chonnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2022, registered Sep 2023).
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies testing escitalopram in Depressive Disorder, Major — 7 open to participants now, 7 under way, 1 of them phase 3. Escitalopram · Depressive Disorder, Major.

Planned enrollment
16th of 99
400 · median 80
Started
2022
with 5 others
No phase
17 of 100
3 open now
Registered
96th of 100
by date

Among the 100 studies testing escitalopram in Depressive Disorder, Major, this one is the 16th largest by planned enrollment of the 99 interventional ones that give a count, is one of 6 that started in 2022, is one of 17 with no phase, and was the 96th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 100 studies testing escitalopram in Depressive Disorder, Major are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About escitalopram

Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing escitalopram in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.

Read the detailed description

This is prospective randomized controlled trials (RCT) to evaluate clinical impact of antidepressant monotherapy vs stepwise psychopharmacotherapy in patients with major depressive disorders, stratified by multimodal serum biomarker scores. Participants will be predicted treatment response based on the multimodal serum biomarker scores at baseline, will be categorized into good and poor treatment responders and then randomly assigned to two groups: stepwise pharmacotherapy group and antidepressant monotherapy group. The hypothesis is that in the good treatment responder, the depression remission will be achieved irrespective of treatment modality (stepwise pharmacotherapy or antidepressant monotherapy) group while in poor treatment responders, the treatment response of stepwise pharmacotherapy will be superior to those of antidepressant monotherapy.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • depression
  • antidepressant monotherapy
  • stepwise psychopharmacotherapy
  • multimodal serum biomarker score
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19 to 65 years
  • -IV criteria for major depressive disorder by study psychiatrists
  • Score≥17 on Hamilton Depression Rating Scale-17
  • With ability to understand the objective of the study and sign
  • Initiation of an antidepressant treatment for the current episode or no psychotropics excluding sleep pills or benzodiazepines within 1 month of participation

Exclusion criteria

Exclusion Criteria:

  • Current or lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, or other psychotic disorders
  • current major depressive disorder with psychotic features
  • History of organic psychosis, epilepsy, or seizure disorder
  • Current anorexia nervosa or obsessive compulsive disorder
  • Unstable or uncontrolled medical condition
  • Unable to complete the psychiatric assessment or comply with the medication regimen due to a severe physical illness
  • History of anticonvulsant treatment
  • Electroconvulsive therapy for the current depressive episode
  • Hospitalization for any psychiatric diagnosis except depressive disorder (e.g., alcohol/drug dependence)
  • severly high risk of suicide, self-harm or homicide by investigator's assessment
  • Pregnant or breastfeeding
  • lack of treatment information on the current depressive episode
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Good responder group-stepwise pharmacotherapy group

    Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then good responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group. In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.

    Drug: stepwise pharmacotherapy

  • Active comparator
    Good responder group-antidepressant monotherapy group

    Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then good responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group. In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.

    Drug: antidepressant monotherapy group

  • Experimental
    Poor responder group-stepwise pharmacotherapy group

    Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then poor responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group. In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.

    Drug: stepwise pharmacotherapy

  • Active comparator
    Poor responder group-antidepressant monotherapy group

    Using multimodal serum biomarker scores, patients will be divided into good/poor responder. Then poor responder group will be randomized into stepwise pharmacotherapy group vs antidepressant monotherapy(escitalopram) group. In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.

    Drug: antidepressant monotherapy group

Interventions

  • DrugEscitalopramStudies of EscitalopramEscitalopram pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.

    Also known as: escitalopram, escitalopram with aripiprazole augmentation, escitalopram with lithium augmentation, escitalopram with mirtazapine combination

  • Drugantidepressant monotherapy group

    In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.

    Also known as: escitalopram monotherapy

06

What researchers measure

Primary outcomes

  1. Remission and treatment response status by Hamilton Depression Rating Scale

    Remission defined by total scores of Hamilton Depression Rating Scale (0-52; higher score indicates severe symptom) ≤7 and treatment response defined as ≥50% decrease in the baseline total scores of Hamilton Depression Rating Scale after stepwise psychopharmacotherapy or antidepressant monotherapy

    Time frame: From baseline to 12 week, 1 year

Secondary outcomes

  1. The changes of Hamilton Rating Scale for Depression total score

    To measure the change of the severity of depressive symptoms using observer rating scale after stepwise psychopharmacotherapy or antidepressant monotherapy

    Time frame: From baseline to 12 week, 1 year

  2. The changes of Hospital Anxiety and Depression Scale total score, depression subscore, anxiety subscore

    The Hospital Anxiety and Depression Scale will be used to measure the change of the severity of depressive symptoms using observer rating scale after stepwise psychopharmacotherapy or antidepressant monotherapy. This scale consists of 14 items with a total score ranging from 0 to 42 and divided into two subscales: 7 items of the anxiety subscale (HADS-A) and 7 items of the depression subscale (HADS-D). Higher scores indicate more severe symptoms.

    Time frame: From baseline to 12 week, 1 year

  3. The changes of Clinical Global Impression-severity and improvement score

    The Clinical Global Impression-severity and improvement score is used to measure the change of the global severity and improvement of depressive symptoms after stepwise psychopharmacotherapy or antidepressant monotherapy. This scale is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. Higher scores indicate more severe psychopathology.

    Time frame: From baseline to 12 week, 1 year

  4. The changes of Brief Psychiatric Rating Scale suicide item score

    Suicidality was evaluated with the suicide-related items on the Brief Psychiatric Rating Scale which assesses the level of 18 symptom constructs such as hostility, suspiciousness, hallucination, and grandiosity. Among the 18 items, suicide item that ranges from 1 (not present) to 7 (extremely severe) will be used to measure the change sof suicidality after stepwise psychopharmacotherapy or antidepressant monotherapy.

    Time frame: From baseline to 12 week, 1 year

  5. The changes of EuroQol-5 Dimension score

    To measure the change of quality of life status after stepwise psychopharmacotherapy or antidepressant monotherapy, EuroQol-5 Dimension is used. This scale has five descriptive questions which may have one of three-level answers and a visual analog scale (VAS) on which patients can mark their current health state. visual analog scale (VAS) on which patients can mark their current health state. The 5 Dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) have three levels of functioning each (no problems, some problems, and unable to/extreme problems) while the visual analog scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: From baseline to 12 week, 1 year

  6. The changes of Social and Occupational Functioning Assessment Scale score

    To measure the change of the social and occupational function after stepwise psychopharmacotherapy or antidepressant monotherapy, Social and Occupational Functioning Assessment Scale is used that ranges from 0 to 100, with lower scores representing lower functioning.

    Time frame: From baseline to 12 week

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug

    Time frame: First dose of study drug to last dose of study drug in the 26-week Treatment Period and 1 year after baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kim JM, Kang HJ, Kim JW, Jhon M, Choi W, Lee JY, Kim SW, Shin IS, Kim MG, Stewart R. Prospective associations of multimodal serum biomarkers with 12-week and 12-month remission in patients with depressive disorders receiving stepwise psychopharmacotherapy. Brain Behav Immun. 2022 Aug;104:65-73. doi: 10.1016/j.bbi.2022.05.012. Epub 2022 May 23. PubMed 35618226 ↗

Individual participant data

Plan to share: No — Participant data (without individual identification data) will be translated into coded data and will be available from the principal investigator (J-M Kim) upon reasonable request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2028, 76 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 76 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Sep 26, 2023
StartActual
Aug 3, 2022
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, site details and index terms
1 update, last Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Minor edits only
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06054321
Lead sponsor
Chonnam National University Hospital
Responsible party
Jae-Min Kim (Professor, Chonnam National University Hospital) — Principal investigator
First posted
Sep 26, 2023
Start date
Aug 3, 2022
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Jae-Min Kim, MD, PhD
Contact
jmkim@chonnam.ac.kr
82-62-220-6043
Hee-Ju Kang, MD, PhD
Contact
hjkang82@chonnam.ac.kr
82-62-220-5961
Jae-Min Kim, MD, PhD
principal investigator · Chonnam National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Escitalopram

Start the discussion